Literature DB >> 11753361

Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing.

Xiaoming Liu1, Qinshi Jiang, S Gary Mansfield, M Puttaraju, Yulong Zhang, Weihong Zhou, Jonathan A Cohn, Mariano A Garcia-Blanco, Lloyd G Mitchell, John F Engelhardt.   

Abstract

Spliceosome-mediated RNA trans-splicing (SMaRT) was investigated as a means for functionally correcting endogenous DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) transcripts using in vitro human cystic fibrosis (CF) polarized airway epithelia and in vivo human CF bronchial xenografts. Recombinant adenovirus (Ad.CFTR-PTM) encoding a pre-therapeutic molecule (PTM) targeted to CFTR intron 9 corrected transepithelial cyclic AMP (cAMP)-sensitive short-circuit current (Isc) in DeltaF508 homozygous epithelia to a level 16% of that observed in normal human bronchial epithelia. Molecular analyses using RT-PCR and western blotting confirmed SMaRT-mediated partial correction of endogenous DeltaF508 messenger RNA (mRNA) transcripts and protein. In an in vivo model of DeltaF508 CF airway epithelia, human CF bronchial xenografts infected with Ad.CFTR-PTM also demonstrated partial correction of CFTR-mediated Cl- permeability at a level 22% of that seen in non-CF xenografts. These results provide functional evidence for SMaRT-mediated repair of mutant endogenous CFTR mRNA in intact polarized CF airway epithelial models.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11753361     DOI: 10.1038/nbt0102-47

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  48 in total

Review 1.  Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing.

Authors:  Mariano A Garcia-Blanco
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 2.  Targeted genetic repair: an emerging approach to genetic therapy.

Authors:  Bruce A Sullenger
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

3.  Splicing factor hSlu7 contains a unique functional domain required to retain the protein within the nucleus.

Authors:  Noam Shomron; Mika Reznik; Gil Ast
Journal:  Mol Biol Cell       Date:  2004-06-04       Impact factor: 4.138

4.  Molecular imaging of gene expression in living subjects by spliceosome-mediated RNA trans-splicing.

Authors:  S Bhaumik; Z Walls; M Puttaraju; L G Mitchell; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

Review 5.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

6.  In vivo excision of a single targeted nucleotide from an mRNA by a trans excision-splicing ribozyme.

Authors:  Dana A Baum; Stephen M Testa
Journal:  RNA       Date:  2005-05-04       Impact factor: 4.942

Review 7.  Non-invasive genetic imaging for molecular and cell therapies of cancer.

Authors:  C Belmar; P-W So; G Vassaux; V Moleiro-Sanemeterio; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2007-11       Impact factor: 3.405

8.  Using 5'-PTMs to repair mutant beta-globin transcripts.

Authors:  Monique N Kierlin-Duncan; Bruce A Sullenger
Journal:  RNA       Date:  2007-06-07       Impact factor: 4.942

9.  CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Authors:  Fatih M Uckun; Sanjive Qazi; Hong Ma; Gregory H Reaman; Lloyd G Mitchell
Journal:  Integr Biol (Camb)       Date:  2015-02       Impact factor: 2.192

Review 10.  Alternative splicing: a pivotal step between eukaryotic transcription and translation.

Authors:  Alberto R Kornblihtt; Ignacio E Schor; Mariano Alló; Gwendal Dujardin; Ezequiel Petrillo; Manuel J Muñoz
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-06       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.